ROSE CLAIRE ANTOINE A-GNP-C
Prescription History 1114677713
Nurse Practitioner - Primary Care in Hamden, CT
NPI Status: Active since March 25, 2022
Prescription History for Informed Healthcare Decisions
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ROSE CLAIRE ANTOINE A-GNP-C, an active Primary Care specialist practicing in Hamden, CT. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 39 documented patient claims. Among these therapy options, the most frequently utilized medication is Modafinil, which accounts for 22 claims alone.
Gabapentin
Generic Formulation: GabapentinSpecialty: Nurse PractitionerProvider Avg Cost Per Claim
$4.61
State Avg Cost Per Claim
$23.37
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.
Modafinil
Generic Formulation: ModafinilSpecialty: Nurse PractitionerProvider Avg Cost Per Claim
$10.28
State Avg Cost Per Claim
$179.34
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
Modafinil reduces extreme sleepiness due to narcolepsy and other sleep disorders, such as periods of stopped breathing during sleep (obstructive sleep apnea). It is also used to help you stay awake during work hours if you have a work schedule that keeps you from having a normal sleep routine (shift work sleep disorder). This medication does not cure these sleep disorders and may not get rid of all your sleepiness. Modafinil does not take the place of getting enough sleep. It should not be used to treat tiredness or hold off sleep in people who do not have a sleep disorder. It is not known how modafinil works to keep you awake. It is thought to work by affecting certain substances in the brain that control the sleep/wake cycle.
Dataset Methodology & CMS Source Information
This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ROSE CLAIRE ANTOINE A-GNP-C provides transparency into local medical care patterns within Hamden, CT.
Key Learning Objectives for this Profile:
- Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
- Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Primary Care** practice concentrations.
- Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
- Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.
Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.
